Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes

Abstract

We assessed the frequency of programmed death-ligand 1 (PD-L1) expression by immunohistochemistry (IHC) in a cohort of 522 sarcomas from 457 patients, incuding a subset of 46 patients with 63 matched samples from local recurrence or metastases with primary tumours and/or metachronous metastases. We also investigated the correlation of PD-L1 with the presence and degree of tumour-infiltrating lymphocytes (TILs) in a subset of cases. IHC was performed using the PD-L1 SP263 companion kit (VENTANA) on tissue microarrays from an archival cohort. Evaluation of PD-L1 and TILs was performed on full sections for a subset of 23 cases. Fisher's exact and Mann Whitney test were used to establish significance (P <0.05). PD-L1 positive expression (�1%) was identified in 31% of undifferentiated pleomorphic sarcomas, 29% of angiosarcomas, 26% of rhabdomyosarcomas, 18% of myxofibrosarcomas, 11% of leiomyosarcomas and 10% of dedifferentiated liposarcomas. Negative expression was present in all atypical lipomatous tumous/well-differentiated lipoasarcomas, myxoid liposarcomas, synovial sarcomas, pleomorphic liposarcomas, and Ewing sarcomas. PD-L1 IHC was concordant in 81% (38 of 47) of matched/paired samples. PD-L1 IHC was discordant in 19% (9 of 47 matched/paired samples), displaying differences in the proportion of cells expressing PD-L1 amongst paired samples with the percentage of PD-L1-positive cells increasing in the metastatic/recurrent site compared to the primary in 6 of 9 cases (67%). Significant correlation between PD-L1 expression and the degree of TILs was exclusively identified in the general cohort of leiomyosarcomas, but not in other sarcoma subtypes or in metastatic/recurrent samples. We conclude that the prevalence of PD-L1 expression in selected sarcomas is variable and likely to be clone dependent. Importantly, we demonstrated that PD-L1 can objectively increase in a small proportion of metastases/recurrent sarcomas, offering the potential of treatment benefit to immune checkpoint inhibitors in this metastatic setting. PLOS ONEPLOS ONE | https://doi.org/10.1371/journal.pone.0222551 April 15, 2020 1 / 17 OPEN ACCESS Citation: Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A, et al. (2020) Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes. PLoS ONE 15(4): e0222551. https://doi.org/10.

When used together SS18–SSX fusion‐specific and SSX C‐terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases

“…We then obtained tissue microarray (TMA) slides from a second cohort comprising unselected sarcomas from Douglass Hanly Moir pathology. The details of this TMA cohort, which was limited to resection specimens, has been reported elsewhere 18 . Briefly, it had been independently reviewed by pathologists with expertise in soft tissue tumours and included two separate 1‐mm cores from each tumour.…”

DNA damage‐inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression

“…The second negative control cohort comprised sections from a tissue microarray (TMA) of unselected sarcomas. The details of this TMA have previously been reported; it comprised two 1‐mm duplicate cores from 543 individual samples from 485 patients, including a range of tumours, including leiomyosarcoma ( n = 119), atypical lipomatous tumour (ALT)/well‐differentiated liposarcoma (WD‐LPS) ( n = 97), myxofibrosarcoma (MFS) ( n = 66), undifferentiated pleomorphic sarcoma (UPS) ( n = 66), dedifferentiated liposarcoma (DD‐LPS) ( n = 40), rhabdomyosarcoma (several types, n = 23), angiosarcoma ( n = 17), synovial sarcoma ( n = 17), Ewing sarcoma ( n = 14), pleomorphic liposarcoma (Pleo‐LPS) ( n = 11), extraskeletal myxoid chondrosarcoma (EMCS) ( n = 10), and others 21,22 . This TMA cohort also included core samples from many of the cases that were also available for whole section IHC.…”

Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report

“…The effectiveness of checkpoint inhibitors in sarcoma may be partially explained by evidence that sarcomas express PD‐1/PD‐L1, with expression ranging from 0% to 33% across all sarcomas and up to 18% in MFS [12]. There remains, however, a need to identify biomarkers to determine who will respond to these therapies [4].…”